Spermosens Net Income From Continuing Ops from 2010 to 2026

9R5 Stock   0  0.0002  16.67%   
Spermosens' Net Loss is decreasing over the last several years with slightly volatile swings. Net Loss is predicted to flatten to about -9.6 M. During the period from 2010 to 2026 Spermosens AB Net Loss regressed destribution of quarterly values had mean deviationof  2,350,952 and mean square error of 8.5 T. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-9.2 M
Current Value
-9.6 M
Quarterly Volatility
3.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Spermosens financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spermosens' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Expense of 762 K or Selling General Administrative of 4.8 M, as well as many indicators such as . Spermosens financial statements analysis is a perfect complement when working with Spermosens Valuation or Volatility modules.
  
This module can also supplement various Spermosens Technical models . Check out the analysis of Spermosens Correlation against competitors.
The Net Income From Continuing Ops trend for Spermosens AB offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Spermosens is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Spermosens' Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Spermosens AB over the last few years. It is Spermosens' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Spermosens' overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Spermosens Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(8,088,258)
Coefficient Of Variation(41.65)
Mean Deviation2,350,952
Median(6,423,000)
Standard Deviation3,368,843
Sample Variance11.3T
Range12.8M
R-Value(0.54)
Mean Square Error8.5T
R-Squared0.29
Significance0.02
Slope(362,106)
Total Sum of Squares181.6T

Spermosens Net Income From Continuing Ops History

2026-9.6 M
2025-9.2 M
2024-10.2 M
2023-12.2 M
2022-19.2 M

About Spermosens Financial Statements

Spermosens stakeholders use historical fundamental indicators, such as Spermosens' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Spermosens investors may analyze each financial statement separately, they are all interrelated. For example, changes in Spermosens' assets and liabilities are reflected in the revenues and expenses on Spermosens' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Spermosens AB. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-9.2 M-9.6 M

Currently Active Assets on Macroaxis

Other Information on Investing in Spermosens Stock

Spermosens financial ratios help investors to determine whether Spermosens Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Spermosens with respect to the benefits of owning Spermosens security.